Ondine Receives Impact Award at IPA World Congress

Ondine Biomedical is recipient of the TAYYABA HASAN IMPACT AWARD at 18th IPA World Congress, Finland

VANCOUVER, BC / ACCESSWIRE / July 17, 2023 / Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Tampere, Finland, for demonstrating exceptional perseverance and clinical acumen. Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2 including deployment in large scale enterprises.

The IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security. The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.

Newly elected President of the IPA Board of Directors, Colin Hopper of UCL, commented, "The international Congress recognizes leaders from around the world, in their respective fields, for their contributions that continue to advance the field of photomedicine. The IPA wishes to congratulate the Ondine team for being recognized as the 2023 recipient of the Tayyaba Hasan IMPACT Award.

"This Team Award recognizes the collective efforts and successes in advancing the clinical safety and efficacy of Photodynamic Therapy for antiviral applications during the COVID-19 pandemic. The outcomes of this work and these studies will help to serve future pandemic preparedness and support the ongoing efforts for advanced antimicrobial resistance stewardship. Antimicrobial resistance is one of the top human health issues globally."

Ondine team member, Cristina Romo, Senior Scientist and Lab Manager, was honoured as an Early Investigator's Award recipient.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

The International Photodynamic Association (IPA)

The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photomedicine, in particular in the areas of photodynamic disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and photodiagnosis (PD). With members and associates from over 30 countries, the IPA represents a truly global community consisting of prominent international scientists, clinical and translational researchers, healthcare professionals and students across academic, hospital, government, and private sector organizations. The IPA promotes the study of diagnosis and treatment using light-activated photosensitizers and disseminates scientific information to its members, the research community, and to the community at large. For more information, please go to the site: International Photodynamic Association (IPA)

The 18th World Congress of the International Photodynamic Association

The Biennial International Photodynamic Association World Congress aims to bring together researchers and clinicians in all fields of Photodynamic Therapy (PDT) and Photodiagnosis (PDD) since 1986. Every two years (with the exception of a 4-year hiatus since the 17th world congress), the IPA organizes a conference to foster scientific development and contribute to clinical practice. The 18th IPA World Congress will be held in Tampere, Finland, July 10-15, 2023. Full details of the Congress are available at https://ipa-2023.com/congress/speakers

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Ondine Biomedical Inc